Skip to main content

Dr.Presso

Category: AI in Healthcare

An AI-powered 'mental-tech' platform that utilizes voice analysis and non-verbal cues to screen for depression and provide personalized mental healthcare through a daily voice diary. Dr.Presso was founded in 2022. The company is led by Jeong Hwan-bo. Based in Seoul, South Korea. Team size: 1-10. Total funding raised: $600K. Latest round: Seed. Key investors include TIPS (Tech Incubator Program for Startup), Chung-Ang University Campus Town, Social Venture EXPO (Musinsa Special Award).

Founded
2022
Headquarters
Seoul, South Korea
Team size
1-10
Total funding
$600K

Value proposition

Lowers the barrier to mental healthcare by using non-verbal voice markers to provide objective psychological screening that is harder to manipulate than traditional text-based questionnaires.

Products and solutions

REDI (레디): An AI voice diary app that analyzes vocal patterns (tone, pitch, speed) and text content to detect signs of depression and provide behavioral prescriptions., Maum Convenience Store (마음편의점): A CBT-based personalized diary service where AI and psychiatrists collaborate to provide feedback on user entries., Precision Mental Health Diagnostic Software: AI-driven solutions for clinical use to monitor emotional risk signals in high-risk groups.

Unique value

First in Korea to commercialize a fusion technology of voice and text for depression screening, focusing on paralinguistic features (how one speaks) rather than just semantic content (what one says).

Target customer

Individuals seeking accessible mental health support (B2C), public healthcare institutions, military organizations, and psychiatric clinics (B2B/B2G)

Industries served

Digital Healthcare, Mental Health Technology (Mental-tech), Artificial Intelligence (Voice/NLP), Public Health & Medical Services

Technology advantage

Led by a Medical Doctor (MD) CEO, the company bridges the gap between clinical psychiatry and AI. Their voice-based markers allow for higher accessibility for elderly or vulnerable populations and enable faster global scaling due to the universal nature of vocal emotional markers.

How they differentiate

Medical Doctor (MD)-led development of 'vocal biomarkers' that analyze paralinguistic features (pitch, tone, speed) rather than just text, providing an objective clinical screening tool for depression that is harder to manipulate than traditional self-report surveys.

Main competitors

Atommer (Mindcafe), BlueSignum, Sonde Health

Key partnerships

Mongolian Central Military Hospital (Cross-border pilot for mental health screening), Chung-Ang University (MOU for Medical AI talent development and R&D), TIPS (Tech Incubator Program for Startups by the Korean Government), Musinsa (Social Venture partnership/EXPO awardee), Gangwon Creative Economy Innovation Center (2026 Gangwon BRIDGE ABC Startup Support Program)

Notable customers

Mongolian Central Military Hospital, Chung-Ang University, Korean Military organizations (pilot)

Major milestones

Founded Dr.Presso in March 2022 by MD Jeong Hwan-bo, Selected for the government-backed TIPS program (2023), Launched 'REDI' AI voice diary app and 'Maum Convenience Store', Winner of the Musinsa Special Award at the 9th Social Venture EXPO (Oct 2024), Received ICT Innovation Award at FIX 2025, Named a Finalist for the 2025 MWC GLOMO Awards (Connected Health and Wellbeing category), Selected to showcase at the CES 2026 Eureka Park Seoul Pavilion, Unveiled AI group therapy earbuds 'Therapods' at CES 2026, Selected for the 2026 Gangwon BRIDGE ABC Startup Support Program (May 2026)

Growth metrics

Selected as a finalist for the MWC 2025 GLOMO Awards and received the ICT Innovation Award at FIX 2025.

Market positioning

Early-stage 'Mental-Tech' innovator specializing in precision psychiatric diagnostics and AI voice diaries.

Geographic focus

South Korea, Mongolia, North America (via CES/MWC global expansion)

Patents and IP

Proprietary AI algorithms for voice-based depression screening and multi-modal emotional risk detection (Specific registration numbers are protected/non-disclosed, but recognized via Korean ICT Innovation Awards).

About Jeong Hwan-bo

Jeong Hwan-bo (Whanbo Jung) is a Medical Doctor (MD) and entrepreneur who specializes in digital healthcare and 'mental-tech' innovation. He founded Dr.Presso in March 2022 with a vision to solve medical and social problems through technology. He previously served as an early member and Chief Medical Officer (CMO) of medical AI company VUNO before founding Doctorpresso. Under his leadership, the company has gained international recognition, becoming a finalist for the MWC 2025 GLOMO Awards and receiving the ICT Innovation Award at FIX 2025.

Official website: